BioCentury | Nov 19, 2019

A vaccine made of red blood cell and tumor cell membranes plus checkpoint blockade for breast cancer, melanoma

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; melanoma Personalized vaccines derived from red blood cells and tumor cells could synergize with checkpoint inhibitors to treat breast cancer and melanoma. The vaccines are created by fusing hemoglobin-depleted...
BioCentury | Jan 12, 2018
Financial News

Truffle Capital raises $102M toward life science and medtech fund

Life sciences and information technology VC Truffle Capital raised $102 million toward its planned $240 million Truffle BioMedTech fund in an initial closing. The Paris-based firm said it remains on track to raise the remaining...
BioCentury | Jan 10, 2018
Financial News

Truffle Capital raises $102M toward life science and medtech fund

Life sciences and information technology VC Truffle Capital raised $102 million toward its planned $240 million Truffle BioMedTech fund in an initial closing. The Paris-based firm said it remains on track to raise the remaining...
BioCentury | Aug 22, 2005
Product Development

Nanotech in the clinic

There has been an enormous amount of hype around nanotechnology since the concept first gained currency in the biomedical field about a decade ago. Now that nanotech-derived therapeutics are entering or nearing the clinic - including...
Items per page:
1 - 4 of 4
BioCentury | Nov 19, 2019

A vaccine made of red blood cell and tumor cell membranes plus checkpoint blockade for breast cancer, melanoma

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; melanoma Personalized vaccines derived from red blood cells and tumor cells could synergize with checkpoint inhibitors to treat breast cancer and melanoma. The vaccines are created by fusing hemoglobin-depleted...
BioCentury | Jan 12, 2018
Financial News

Truffle Capital raises $102M toward life science and medtech fund

Life sciences and information technology VC Truffle Capital raised $102 million toward its planned $240 million Truffle BioMedTech fund in an initial closing. The Paris-based firm said it remains on track to raise the remaining...
BioCentury | Jan 10, 2018
Financial News

Truffle Capital raises $102M toward life science and medtech fund

Life sciences and information technology VC Truffle Capital raised $102 million toward its planned $240 million Truffle BioMedTech fund in an initial closing. The Paris-based firm said it remains on track to raise the remaining...
BioCentury | Aug 22, 2005
Product Development

Nanotech in the clinic

There has been an enormous amount of hype around nanotechnology since the concept first gained currency in the biomedical field about a decade ago. Now that nanotech-derived therapeutics are entering or nearing the clinic - including...
Items per page:
1 - 4 of 4